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Abstract
Chitin is an essential structural component of the fungal cell wall. Chitinases are thought to be
important for fungal cell wall remodelling, and inhibition of these enzymes has been proposed as a
potential strategy for development of novel anti-fungals. The fungal pathogen Aspergillus fumigatus
possesses two distinct multi-gene chitinase families. Here we explore acetazolamide as a chemical
scaffold for the inhibition of an A. fumigatus ‘plant-type’ chitinase. A co-crystal structure of AfChiA1
with acetazolamide was used to guide synthesis and screening of acetazolamide analogues that
yielded SAR in agreement with these structural data. Although acetazolamide and its analogues are
weak inhibitors of the enzyme, they have a high ligand efficiency and as such are interesting leads for
future inhibitor development.
1. Introduction
Aspergillus fumigatus is the causative agent of aspergillosis, a life-threatening fungal infection that
targets a rising population of immunocompromised patients.  Currently available anti-fungal drugs,
such as the azoles, amphotericin B and the candins are only partially effective  and resistant
Aspergillus strains have started to appear in hospital settings.  Thus there is a need for the
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identification of novel targets and the development of new anti-fungal agents. Enzymes involved in
the biogenesis/turnover of the fungal cell wall are thought to represent possible targets.
Chitin, a polymer of β(1,4)-linked N-acetylglucosamine (GlcNAc), is an essential structural
component of the fungal cell wall, giving it structural rigidity and chemical/biological stability.
Because of the inherent rigidity of chitin, fungi need to partially hydrolyse the chitin layer for cell
division and morphogenesis, which is carried out by family 18 chitinases.  Two subclasses of family 18
chitinases exist: the ‘bacterial-type’ chitinases are found in bacteria, fungi and mammals; the
‘plant-type’ chitinases are found exclusively in plants and fungi. Whereas the ‘bacterial-type’ enzymes
are invariably secreted and mostly possess exochitinase activity,  the ‘plant-type’ chitinases are
frequently cell wall associated and possess endochitinase activity. Several studies have shown that
these enzymes are involved in yeast mother–daughter cell separation.  Because these enzymes are
not intracellular, it is possible to explore a wider area of chemical space for inhibitors, as these would
not be required to cross membranes. Whilst humans possess two active chitinases,  they are of the
‘bacterial-type’, and to date the only inhibitors reported are the large, hydrophilic natural products,
allosamidin,  argifin,  argadin  and the rationally designed drug-like inhibitor C -dicaffeine.
There are five ‘plant-type’ chitinases genes in the A. fumigatus genome (AfChiA1–5), with a currently
unknown transcription profile. Sequence alignments show that they have a high degree of structural
similarity in the active site, suggesting that it should be possible to design compounds that inhibit all
five enzymes.
Recently we have cloned and over-expressed the ‘plant-type’ family 18 chitinase Cts1p from
Saccharomyces cerevisiae (ScCTS1).  This enzyme was then screened against the Prestwick chemical
library of 880 drug-like molecules. From this, three significant hits were identified,
8-chlorotheophylline, acetazolamide and kinetin (Table 1), all of which were competitive inhibitors of
the enzyme and were shown to bind in the active site groove, interacting with the catalytic
machinery.
Here we describe a study towards the identification of small inhibitor scaffolds (‘fragments’) against
the ‘plant-type’ A. fumigatus enzyme chitinase A1 (AfChiA1). Two novel ScCTS1 inhibitors,
acetazolamide and 8-chlorotheophylline, showed weak inhibition of AfChiA1. We were able to obtain
a crystal structure of AfChiA1 in complex with acetazolamide. A number of derivatives of
acetazolamide were prepared or purchased and screened against the enzyme AfChiA1; a number were
identified with similar activity to acetazolamide.
2. Results and discussion
2.1. Acetazolamide is an efficient inhibitor of A. fumigatus chitinase
Previous work has suggested that the plant-type fungal chitinases may be targets for novel anti-fungal
strategies.  So far the only enzyme from this class characterised in some detail is CST1 from S.
cerevisiae and the plant enzyme hevamine.  A. fumigatus chitinase A1 (AfChiA1) also belongs to the
class of plant-type chitinases family, and has been cloned and characterised recently.
To identify possible inhibitors of AfChiA1, a number of plant-type chitinase inhibitors previously
characterised against ScCTS1 were explored as potential scaffolds (Table 1).  Allosamidin is an
extensively characterised natural product inhibitor of both plant-type and bacterial-type family 18
chitinases,  and has recently been reported to competitively inhibit ScCTS1 with a K  of 0.61 µM
and hevamine with a K  of 3.1 µM.  Unfortunately, allosamidin is a substrate analogue with poor
drug-like properties (high molecular weight, containing glycosidic bonds and an undesirably low
C log P of −5.2) and the total synthesis is costly and complicated.  Remarkably, allosamidin only
weakly inhibits AfChiA1 (IC  = 127 µM, Fig. 1),  which is 30- and 200-fold less potent than values
previously reported against hevamine and ScCTS1, respectively. Examination of the purine derivative
8-chlorotheophylline, which had previously been demonstrated to inhibit ScCTS1 with a K  of
600 µM,  revealed a similar level of inhibition (IC  = 410 µM, Fig. 1). Two further compounds,
kinetin and acetazolamide, have been identified as ScCTS1 inhibitors by screening the Prestwick
Chemical Library, with K  values of 3.2 µM and 21 µM, respectively.  Kinetin failed to show any
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discernable effect against AfChiA1 even at concentrations in excess of 1 mM; acetazolamide on the
other hand inhibited AfChiA1 with an IC  of 164 µM (Fig. 1), which is an order of magnitude less
potent than previously demonstrated against ScCTS1 but not dissimilar to the level of inhibition
observed for allosamidin (Fig. 1). It is instructive to compare the ligand efficiencies of the compounds
at this stage—that is, the binding energy per non-hydrogen atom.  Due to their small size
acetazolamide and 8-chlorotheophylline are the most efficient of these inhibitors (−0.61 and
−0.57 kcal mol  atom , respectively), compared to allosamidin (−0.19 kcal mol  atom ). Thus,
acetazolamide is a small drug-like molecule that is amenable to preparation of analogues and
represents an attractive starting point for further elaboration.
2.2. Crystal structure of the AfChiA1–acetazolamide complex suggests possible derivatives
Of the initial leads investigated, acetazolamide was selected as the most promising starting point for
the development of A. fumigatus plant-type chitinase inhibitors given its high ligand efficiency.
AfChiA1 crystals, reported previously , were soaked with acetazolamide, diffraction data were
collected to 2.0 Å resolution, and the structure of the AfChiA1–acetazolamide complex was solved by
molecular replacement and refined to an R  of 0.249 (Table 2) with good stereochemistry. Electron
density for the ligand acetazolamide can be seen in both molecules in the asymmetric unit, but it is
less clear in chain A, where the active site is partially occluded by a symmetry-related protein
molecule. Thus the further discussion of the structure will focus on chain B only, which is less
impacted and has a more accessible active site.
The overall binding mode of the ligand to AfChiA1 is essentially identical to that observed for ScCTS1
(Fig. 2B).  The thiadiazole ring stacks with the conserved Trp312, while its ring nitrogens accept
hydrogen bonds from the backbone amides of Ala124 and Tyr125, in the latter case indirectly via an
active site-bound water molecule. The acetamido group enters, and essentially fills, the small AfChiA1
active site pocket formed by Tyr238, Gln230, Met310, Ala205, Tyr34 and Asp172. It is oriented by two
hydrogen bonds, one from its amide to the side chain of Asp172 and one from the Tyr232 side chain
hydroxyl to its carbonyl oxygen. The sulfonamide group on the other hand forms few direct
interactions with the protein: it accepts a poor hydrogen bond from the Trp312 side chain and
otherwise points away from the protein and into the bulk solvent.
The unexpectedly poor inhibition of AfChiA1 by kinetin can be explained by the presence of
methionine 310 in the AfChiA1 active site, which replaces an alanine in the corresponding position in
ScCTS1 (Fig. 2A), a substitution found in all A. fumigatus plant-type chitinases. These residues define
the bottom of the active site pocket that accepts the furanyl group of kinetin.  While the pocket is still
present in AfChiA1, it is shallower due to the larger Met310 side chain (Fig. 2), rendering it unable to
accommodate bulky ligands like kinetin.
A. fumigatus is predicted to possess five plant-type GH18 chitinases (AfChiA1–5) that may have
overlapping, if not interchangeable, functions. Thus, for an inhibitor to be useful in vivo, it would
have to bind effectively to all five AfChiA active sites. The AfChiA1 sequence in Fig. 2A is shaded
based on a sequence alignment of AfChiA1–5, indicating residues identical among all five proteins in
purple, residues conserved among four or fewer proteins in shades of blue and completely
non-conserved residues in white. The same colouring has also been applied to the AfChiA1 active site
surface shown in Fig. 2C, demonstrating that, with the exception of the non-conserved but flexible
Tyr125,  the part of the active site cleft interacting with acetazolamide is completely conserved
among all five A. fumigatus plant-type chitinases. This suggests that acetazolamide could bind
similarly, both in orientation and in affinity, to these five enzymes. Fig. 2C also highlights additional
conserved active site areas that could be used for the further elaboration of the ligand.
To investigate in silico the potential for such elaboration, we used the docking program LIGTOR  to
screen for beneficial substitutions/modifications of either the acetamido or the sulfonamide group,
while keeping the rest of the molecule constant. Not surprisingly, the scope for modification at the
acetamido group is limited. Docking runs predict that a slight increase in size of this group, for
example, by substituting a trifluoroacetamido moiety, could improve overall binding affinity, and even
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an additional methyl group, yielding a propionamido group, may be tolerated with slight changes to
the overall binding mode, but anything larger (including, e.g., isobutyramido groups) cannot be
accommodated in the active site pocket and would most likely abolish binding.
Modifications/substitutions of the sulphonamide group on the other hand face the opposite problem:
as the ligand is essentially pointing away from the active site, most small modifications are tolerated
but do not yield additional interactions between ligand and protein. Larger additions to the existing
scaffold may be able to interact with additional parts of the AfChiA1 active site, but the required
flexibility of such ligands and the corresponding entropy cost associated with orienting the flexible
parts on binding to the protein could negate any positive effects on the predicted ligand affinity. To
test these computational predictions, a number of acetazolamide derivatives were either synthesised
or obtained from commercial suppliers and their binding to AfChiA1 was investigated.
2.3. Synthesis and screening of acetazolamide derivatives
As acetozolamide provided an attractive small molecule starting point for a rational focused inhibitor
screen, including a structurally defined binding mode, a number of analogues were screened against
AfChiA1 (Table 3). The acetazolamide analogues were either synthesised (Scheme 1) or acquired from
commercial sources. The synthesis of compounds carried out to is shown in the scheme.
Compounds were screened against AfChiA1 in duplicate. The assay performance statistics generated
from screening plates were well within acceptable screening parameters (Z′ 0.72 ± 0.04) and the
replicate potency determinations correlated well, yielding errors below 45% for all bar one compound
(Table 3).
The structures of the compounds allowed determination of the effects of changing the both the
sulphonamide (R  in Table 3) and acetamide (R ) portions of the molecule. The screen gave a number
of compounds with potencies in the 100–500 µM range, that is, similar to the parent compound. A
few trends in the SAR can be deduced. Increasing the size of the acetamide moiety by adding an extra
methyl (2) or a chloro (20 and 21) substituent leads to a reduction in activity, while substitution with
a trifluoroacetamide group (compare 11 and 15) is energetically neutral or slightly favourable; this is
in accordance with the structural and docking data, as the methyl of the acetamide group essentially
fills the active site pocket as described above. At the same time ‘deacetylating’ R  to a free amine also
abolishes inhibitory activity (cf. 6). Replacement of the sulphonamide is generally tolerated: –SH,
–Ph, –CF  and –Br substituents as R  (9–12) produce compounds with similar activity to
acetazolamide (1). This is perhaps not surprising as the sulphonamide group does not appear to make
significant interactions with the protein. Nonetheless the R  substituent does affect affinity as its
removal (R  = –H, 7) or replacement with a methyl (R  = –CH , 8) again abrogate activity.
3. Conclusion
A. fumigatus contains five plant-type GH18 chitinases; based on the structural information for
AfChiA1, it is predicted that the acetazolamide binding sites of AfChiA1–5 are identical, suggesting it
may be possible to develop compounds that inhibit all of these enzymes. We have previously reported
various inhibitors of ScCTS1; these showed different inhibition profiles against AfChiA1; in particular
the binding pocket which accommodated the acetamide group is much smaller in the case of AfChiA1
compared to ScCTS1. The most promising inhibitor was acetazolamide. Although acetazolamide and
various analogues did not show very potent inhibition, they have relatively low molecular weights.
Ligand efficiency is a good way to characterise how efficiently these core scaffolds bind and the
potential for them to be optimised to low nanomolar compounds.  Some of the compounds (Table 3)
have ligand efficiencies of better than −0.3 kcal mol  atom . Therefore these possess the potential to
be elaborated to compounds with IC  of <10 nM and molecular weight of <500, provided good
binding interactions are retained. Most of the interactions with the protein are focused around the
amide bond and thiadiazole ring. There is not much scope for further substitution of the acetyl group
as the methyl nearly completely occupies a small pocket. However the sulphonamide does not appear
to make strong interactions and it is possible to replace this. Therefore optimisation will have to focus
on substitution or replacement of this sulphonamide and enhancement of the interactions of the
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4.4.1. Synthesis of 5-amino-2-sulfamoyl-1,3,4-thiadiazole monohydrochloride (6)
thiadiazole core with the protein.
4. Experimental
4.1. Expression and purification
AfChiA1 Ser29-Leu335 was expressed and purified as described previously.  Briefly, the enzyme was
expressed in Pichia pastoris as a secreted protein. The culture supernatant was subjected to dialysis
and concentration, then AfChiA1 was purified using anion exchange chromatography followed by gel
filtration. The resulting pure AfChiA1 protein was used for both kinetic analysis and crystallization
trials.
4.2. Crystallisation and structure solution
The protein was concentrated to 36 mg mL  and crystallized by hanging drop vapour diffusion as
described previously.  Acetazolamide was incorporated by adding the solid ligand to a crystal-
containing drop and incubating for 30 min at room temperature. After cryoprotection by short
immersion in 2.5 M Li SO , data were collected at 100 K on beamline ID14-EH3 at the European
Synchrotron Radiation Facility (ESRF, Grenoble, France).
Data were processed and scaled to 2.0 Å using HKL software  and the structure was solved by
molecular replacement with AMoRe  using the AfChiA1 apo-structure  as a search model.
Refinement of the AfChiA1–acetazolamide complex structure proceeded through rounds of
minimisation with REFMAC5  and model building with Coot.  Ligand coordinates and topologies
were generated with PRODRG.  PyMol  and ALINE  were used in the preparation of Fig. 2.
4.3. AfChiA1 inhibition assays
AfChiA1 activity was assayed in McIlvain’s buffer (pH 5.5).  The final reaction mixture consisted of
AfChiA1 (10 nM), 0.05 mg/mL BSA (Thermo) and 4-methylumbelliferyl β-D-N,N
′,N″-triacetylchitotrioside (Sigma) (100 µM). Final assay volume was 42 µl in 384-well black
polystyrene plates with a final dimethyl sulphoxide (DMSO) concentration of 1% in all samples,
including controls. Test and standard compound concentrations ranged from 1000 to 0.15 µM and
10,000 to 1.5 µM, respectively.
Test and standard compounds were placed into columns 1 and 13 of a 384-well polypropylene plate
and then serially diluted in 100% DMSO through half log increments using a JANUS 8-channel
Varispan automated workstation (PerkinElmer). This produced a compound source plate containing
30 test and 2 standard compounds curves (100 × final assay concentration). From this source plate,
0.42 µl of each compound concentration was then stamped into replicate black 384-well polystyrene
assay plates using a Hummingbird (Genomic Solutions).
To the assay plates, 20.8 µl AfChiA1 (20 nM) was added to all wells with the exception the negative
controls. The reaction was initiated by the addition of 20.8 µl of (200 µM) 4-methylumbelliferyl
β-D-N,N′,N″-triacetylchitotrioside (stock concentration 200 µM), both previous additions were
executed using a FlexDrop reagent dispenser (PerkinElmer).
Assay plates were then incubated on a microtitre plate shaker (Heidolph) at room temperature for
70 min. Fluorescence generated from the release of 4-methylumbelliferone was quantified using an
Envision 2102 Multilabel Reader (PerkinElmer) equipped with 340 nm excitation (band width
60 nm) and 460 nm emission (band width 25 nm) filters.
ActivtyBase (Abase) version 5.4 from IDBS was used for the data processing and analysis. All curve
fitting was undertaken using a 4 Parameter Logistic dose–response curve using XLFit 4.2 Model 205.
4.4. Compound Synthesis
Hydrochloric acid (70 mL,
70.00 mmol, 5.2 equiv) was added to acetazolamide (2.995 g, 13.34 mmol, 1.0 equiv) and the mixture
stirred for 3 h at reflux. The crude material was purified by column chromatography (CHCl /MeOH:
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4.4.2. Synthesis of 5-propylamido-2-sulfamoyl-1,3,4-thiadiazole (2)
4.4.3. Synthesis of 5-butyramido-2-sulfamoyl-1,3,4-thiadiazole (3)
4.4.4. Synthesis of 5-(2-methyl-propylamido)-2-sulfamoyl-1,3,4-thiadiazole (4)
4.4.5. Synthesis of 5-benzylamido-2-sulfamoyl-1,3,4-thiadiazole (5)
4.4.6. Synthesis of 5-acetamido-1,3,4-thiadiazole (7)
100/0 to 70/30) to yield the product (2.768 g, 96%); mp 179–180 °C; R  = 0.26 (CHCl /MeOH:
80/20); δ  (500 MHz, DMSO) 7.91 (2H, br s, NH -6), 8.09 (3H, s, NH -7); δ  (125 MHz, DMSO)
157.8 (C-2), 171.6 (C-5); m/z (ES ): 181.1 ([M+H−Cl] , 100%); HRMS (ES ) 180.9849. ([M+H−Cl]
C H N O S  requires 180.9848).
5-Amino-2-sulfamoyl-1,3,4-thiadiazole
monohydrochloride (218 mg, 1.01 mmol, 1.0 equiv) was dissolved in DCM (6 mL). Triethylamine
(0.30 mL, 2.16 mmol, 2.1 equiv) was added and the solution stirred for 1.5 h at rt. Then, propionyl
chloride (0.20 mL, 2.26 mmol, 2.2 equiv) was slowly added and the mixture left stirring for 1.5 h at rt.
Water (1 mL) was added and the precipitate filtered and dried under vacuum. The solid (158 mg) was
purified by column chromatography (CHCl /MeOH: 100/0 to 78/22) to yield the product (32 mg,
13%); mp 253–255 °C; R  = 0.58 (CHCl /MeOH: 80/20); δ  (500 MHz, DMSO) 1.12 (3H, t, H-10,
J = 7.5), 2.55 (2H, q, H-9, J = 7.5), 8.34 (2H, br s, NH -6), 13.00 (1H, br s, NH-7); δ  (125 MHz,
DMSO) 8.8 (C-10), 28.2 (C-9), 161.2 and 164.1 (C-2 and C-5), 173.0 (C-8); m/z (ES ): 237.0
([M+H] , 100%), 495.0 ([2M+H] , 71%); HRMS (ES ) 237.0101. ([M+H]  C H N O S  requires
237.0111).
5-Amino-2-sulfamoyl-1,3,4-thiadiazole
monohydrochloride (286 mg, 1.32 mmol, 1.0 equiv) was dissolved in DCM (7 mL). Triethylamine
(0.35 mL, 2.51 mmol, 1.9 equiv) was added and the solution stirred for 1.5 h at rt. Then, butyryl
chloride (0.25 mL, 2.36 mmol, 1.8 equiv) was slowly added and the mixture left stirring for 4 h at rt.
Water (1 mL) was added and the precipitate filtered and dried under vacuum. The solid (90 mg) was
purified by column chromatography (CHCl /MeOH: 100/0 to 78/22) to yield the product (79 mg,
24%); mp 244–246 °C; R  = 0.54 (CHCl /MeOH: 80/20); δ  (500 MHz, DMSO) 0.91 (3H, t, H-11,
J = 7.4), 1.65 (2H, sext, H-10, J = 7.4), 2.52 (2H, m, H-9), 8.33 (2H, br s, NH -6), 12.99 (1H, br s,
NH-7); δ  (125 MHz, DMSO) 13.4 (C-11), 17.9 (C-10), 36.7 (C-9), 161.1 and 164.2 (C-2 and C-5), 172.2
(C-8); m/z (ES ): 251.0 ([M+H] , 73%); 523.0 ([2M+H] , 100%); HRMS (ES ) 251.0257. ([M+H]
C H N O S  requires 251.0267).
5-Amino-2-sulfamoyl-1,3,4-
thiadiazole monohydrochloride (274 mg, 1.26 mmol, 1.0 equiv) was dissolved in DCM (7 mL).
Triethylamine (0.35 mL, 2.51 mmol, 2.0 equiv) was added and the solution stirred for 1.5 h at rt.
Then, isobutyryl chloride (0.25 mL, 2.34 mmol, 1.9 equiv) was slowly added and the mixture left
stirring for 2 h at rt. Water (1 mL) was added and the precipitate filtered and dried under vacuum.
The solid was purified by column chromatography (CHCl /MeOH: 100/0 to 80/20) to yield the
product (90 mg, 26%); mp 254–255 °C; R  = 0.65 (CHCl /MeOH: 80/20); δ  (500 MHz, DMSO) 1.16
(6H, d, H-10, J = 6.9), 2.82 (1H, Sept, H-9, J = 6.8), 8.34 (2H, br s, NH -6), 13.01 (2H, br s, NH-7);
δ  (125 MHz, DMSO) 18.9 (C-10), 33.9 (C-9), 161.3 and 164.3 (C-2 and C-5), 176.1 (C-8); m/z (ES ):
523.0 ([2M+Na] , 100%), 251.0 ([M+H] , 33%); HRMS (ES ) 251.0272. ([M+H]  C H N O S
requires 251.0267).
5-Amino-2-sulfamoyl-1,3,4-thiadiazole
monohydrochloride (315 mg, 1.45 mmol, 1.0 equiv) was dissolved in DCM (7 mL). Triethylamine
(0.40 mL, 2.87 mmol, 2.0 equiv) was added and the solution stirred for 1.5 h at rt. Then, benzoyl
chloride (0.30 mL, 2.56 mmol, 1.8 equiv) was slowly added and the mixture left stirring for 2.5 h at rt.
Water (1 mL) was added and the precipitate filtered and dried under vacuum. The solid (317 mg) was
purified by column chromatography (CHCl /MeOH: 100/0 to 78/22) to yield the product (36 mg,
09%); mp 260–261 °C; R  = 0.66 (CHCl /MeOH: 80/20); (found: C, 38.3; H, 3.2; N, 17.9; S, 21.2.
C H N O S ·0.7MeOH requires C, 38.0; H, 3.5; N, 18.3; S, 20.9); δ  (500 MHz, DMSO) 7.60 (2H, dt,
H-11, J = 7.8, 1.8), 7.71 (1H, tt, H-12, J = 7.4, 1.2), 8.16 (2H, dd, H-10, J = 8.3, 1.1), 8.38 (2H, br s,
NH -6), 13.55 (1H, br s, NH-7); δ  (125 MHz, DMSO) 128.6 and 128 (C-10 and C-11), 130.9 (C-9),
133.4 (C-12), 162.2 and 164.7 (C-2 and C-5), 165.7 (C-8); m/z (ES ): 285.0 ([M+H] , 100%), 569.0
([2M+H] , 20%); HRMS (ES ) 285.0102. ([M+H]  C H N O S requires 285.0111).
2-Amino-1,3,4-thiadiazole (161 mg, 1.54 mmol,
1.0 equiv) was dissolved in DCM (2 mL). Acid chloride (0.15 mL, 2.11 mmol, 1.4 equiv) was slowly
f 3
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4.4.7. 5-Acetamido-2-thiol-1,3,4-thiadiazole (9)
4.4.8. 5-Amino-2-methyl-1,3,4-thiadiazole (19)
added (exothermic), and the mixture stirred for 5 h at rt. The solution was concentrated after addition
of H O (1 mL). The crude product was purified by column chromatography (CHCl /MeOH: 100/0 to
90/10) to yield the product (38 mg, 17%); mp 276–277 °C; R  = 0.83 (CHCl /MeOH: 80/20); (found:
C, 33.9; H, 3.4; N, 27.6; Cl, 21.8. C H N OS·0.03HCl·0.18MeOH requires C, 33.5; H, 3.8; N, 28.0; S,
21.4); δ  (500 MHz, DMSO) 2.20 (3H, s, H-8), 9.15 (1H, s, H-2), 12.55 (1H, br s, NH-6); δ
(125 MHz, DMSO) 22.4 (C-8), 148.5 (C-5), 158.5 (C-2), 168.6 (C-7); m/z (ES ): 144.0 ([M+H] ,
60%), 166.0 ([M+Na] , 100%); HRMS (ES ) 144.0226. ([M+H]  C H N OS requires 144.0226).
5-Amino-1,3,4-thiadiazole-2-thiol (554 mg, 4.08 mmol,
1.0 equiv), acetic anhydride (1.8 mL, 19.08 mmol, 4.7 equiv) and concd sulphuric acid (20 mL,
0.37 mmol, 0.09 equiv) were stirred for 30 min on a steam bath. After cooling, the mixture was
concentrated under vacuum, and then purified by column chromatography (CHCl /MeOH: 100/0 to
70/30) to yield the product (22 mg, 03%); mp 293–295 °C; R  0.24 (CHCl /MeOH: 90/10); (found:
C, 28.1; H, 3.0; N, 22.5; S, 35.1. C H N OS ·0.3MeOH requires C, 27.9; H, 3.4; N, 22.7; S, 34.7); δ
(500 MHz, DMSO) 2.14 (3H, s, H-9), 12.45 (1H, br s, NH-7), 14.06 (1H, br s, SH-6); δ  (125 MHz,
DMSO) 22.3 (C-9), 152.2 (C-5), 169;4 (C-8), 183.5 (C-2); m/z (ES ): 176.0 ([M+H] , 100%); HRMS
175.9946. ([M+H]  C H N OS  requires 175.9947).
Acetyl chloride (0.50 mL, 7.04 mmol, 2.2 equiv) was slowly
added to thiosemicarbazide (291 mg, 3.16 mmol, 1.0 equiv) and the mixture stirred for 4 h at rt. A
solution of NaOH 50% was added till pH 12–14, and the mixture concentrated under vacuum. The
crude material was purified by column chromatography (CHCl /MeOH: 100/0 to 91/09) to yield the
product (85 mg, 23%); mp 273–274 °C; R  = 0.79 (CHCl /MeOH: 80/20); (found: C, 31.9; H, 4.4; N,
35.4; S, 27.4. C H N S·0.05AcOH requires C, 31.5; H, 4.4; N, 35.6; S, 27.1); δ  500 MHz, DMSO 2.17
(3H, s, H-7), 13.15 (2H, br s, NH -6); δ  (125 MHz, DMSO) 10.8 (C-7), 148.8 (C-5), 165.8 (C-2); m/z
(ES ): 115.8 ([M+H] , 100%); 253.2 ([2M+Na] , 100%); HRMS (ES ) 116.0275. ([M+H]  C H N S
requires 116.0277).
Acknowledgements
This work was supported by a Wellcome Trust Award (Grant Number 081745). DvA is supported by a
Wellcome Trust Senior Research Fellowship. We thank the European Synchrotron Radiation Facility,
Grenoble, for the time at beamline ID14-EH3. The structure has been deposited in the Protein Data
Bank (PDB id 2XTK).
References and notes
1. Zaoutis T.E., Heydon K., Chu J.H., Walsh T.J., Steinbach W.J. Pediatrics. 2006;117:711.
2. Gallien S., Fournier S., Porcher R., Bottero J., Ribaud P., Sulahian A., Socie G., Molina J.M.
Infection. 2008;36:533. [PubMed: 19011743]
3. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., Kern W.V.,
Marr K.A., Ribaud P., Lortholary O., Sylvester R., Rubin R.H., Wingard J.R., Stark P., Durand C.,
Caillot D., Thiel E., Chandrasekar P.H., Hodges M.R., Schlamm H.T., Troke P.F., de Pauw B. N. Engl.
J. Med. 2002;347:408. [PubMed: 12167683]
4. van der Linden J.W., Jansen R.R., Bresters D., Visser C.E., Geerlings S.E., Kuijper E.J., Melchers
W.J., Verweij P.E. Clin. Infect. Dis. 2009;48:1111. [PubMed: 19272019]
5. Snelders E., van der Lee H.A., Kuijpers J., Rijs A.J., Varga J., Samson R.A., Mellado E., Donders
A.R., Melchers W.J., Verweij P.E. PLoS Med. 2008;5:219.
6. Cantarel B.L., Coutinho P.M., Rancurel C., Bernard T., Lombard V., Henrissat B. Nucleic Acids Res.
2009;37:D233. [PMCID: PMC2686590] [PubMed: 18838391]
7. Brurberg M.B., Nes I.F., Eijsink V.G. Microbiology (Reading, England) 1996;142:1581.
8. Terwisscha van Scheltinga A.C., Kalk K.H., Beintema J.J., Dijkstra B.W. Structure. 1994;2:1181.
[PubMed: 7704528]
2 3
f 3
4 5 3
H C
+ +
+ + +
4 6 3
3
f 3
4 5 3 2 Η
C
+ +
+
4 6 3 2
3
f 3
3 5 3 Η
2 C
+ + + + +
3 6 3
Acetazolamide-based fungal chitinase inhibitors
7 of 14
9. Bokma E., Barends T., Terwissch van Scheltingab A.C., Dijkstr B.W., Beintema J.J. FEBS Lett.
2000;478:119. [PubMed: 10922481]
10. Taib M., Pinney J.W., Westhead D.R., McDowall K.J., Adams D.J. Arch. Microbiol. 2005;184:78.
[PubMed: 16096835]
11. Kuranda M.J., Robbins P.W. J. Biol. Chem. 1991;266:19758. [PubMed: 1918080]
12. Dunkler A., Walther A., Specht C.A., Wendland J. Fungal Genet. Biol. 2005;42:935.
[PubMed: 16214381]
13. Bussink A.P., van Eijk M., Renkema G.H., Aerts J.M., Boot R.G. Int. Rev. Cytol. 2006;252:71.
[PubMed: 16984816]
14. Boot R.G., Blommaart E.F., Swart E., Ghauharali-van der Vlugt K., Bijl N., Moe C., Place A., Aerts
J.M. J. Biol. Chem. 2001;276:6770. [PubMed: 11085997]
15. Sakuda S., Isogai A., Matsumoto S., Suzuki A. J. Antibiot. 1987;40:296. [PubMed: 3570982]
16. Arai N., Shiomi K., Iwai Y., Omura S. J. Antibiot. 2000;53:609. [PubMed: 10966077]
17. Houston D.R., Shiomi K., Arai N., Omura S., Peter M.G., Turberg A., Synstad B., Eijsink V.G., van
Aalten D.M. Proc. Natl. Acad. Sci. U.S.A. 2002;99:9127. [PMCID: PMC123105] [PubMed: 12093900]
18. Schuttelkopf A.W., Andersen O.A., Rao F.V., Allwood M., Lloyd C., Eggleston I.M., van Aalten D.M.
J. Biol. Chem. 2006;281:27278. [PubMed: 16844689]
19. Hurtado-Guerrero R., van Aalten D.M.F. Chem. Biol. 2007;14:589. [PubMed: 17524989]
20. Takaya N., Yamazaki D., Horiuchi H., Ohta A., Takagi M. Biosci. Biotechnol. Biochem.
1998;62:60. [PubMed: 9501518]
21. Rush C.L., Schuttelkopf A.W., Hurtado Guerrero R., Blair D.E., Ibrahim A.F.M., Desvergnes S.,
Eggleston I.M., Van Aalten D.M.F. Chem. Biol. 2010
22. Rao F.V., Houston D.R., Booth R.G., Aerts J.M.F.G., Sakuda S., Van Aalten D.M.F. J. Biol. Chem.
2003;278:20110. [PubMed: 12639956]
23. Berecibar A., Grandjean C., Siriwardena A. Chem. Rev. 1999;99:779. [PubMed: 11749432]
24. Hopkins A.L., Groom C.R., Alex A. Drug Discov. Today. 2004;9:430. [PubMed: 15109945]
25. Laskowski R.A., Macarthur M.W., Moss D.S., Thornton J.M. J. Appl. Crystallogr. 1993;26:283.
26. Otwinowski Z.a.M.W. In: Processing of X-ray Diffraction Data Collected in Oscillation Mode.
Carter C.W. Jr., Sweet R.M., editors. Academic Press; New York: 1997.
27. Navaza J. Acta Crystallogr. D Biol. Crystallogr. 2001;57:1367. [PubMed: 11567147]
28. Murshudov G.N., Vagin A.A., Dodson E.J. Acta Crystallogr. D Biol Crystallogr. 1997;53:240.
[PubMed: 15299926]
29. Emsley P., Cowtan K. Acta Crystallogr. D Biol Crystallogr. 2004;60:2126. [PubMed: 15572765]
30. Schuttelkopf A.W., van Aalten D.M. Acta Crystallogr. D Biol. Crystallogr. 2004;60:1355.
[PubMed: 15272157]
31. DeLano, W. L.; DeLano Scientific, San Carlos, CA, USA, 2002, http://www.pymol.org.
32. Bond C.S., Schuttelkopf A.W. Acta Crystallogr. D Biol. Crystallogr. 2009;65:510.
[PubMed: 19390156]
33. MacIlvaine T.C. J. Biol. Chem. 1921;49:183.
Figures and Tables
Acetazolamide-based fungal chitinase inhibitors
8 of 14
Figure 1
IC  curves determined in triplicate, fitted to a four-parameter logistic dose–response curve
(minimum, Hill slope, inflection point and maximum) against AfChiA1 for allosamidin
(IC  = 128 µM, Hill slope 0.9), acetazolamide (IC  = 164 µM, Hill slope 1.1) and
8-chlorotheophylline (IC  = 410 µM, Hill slope 1.0) using 4-methylumbelliferyl β-D-N,N
′,N″-triacetylchitotrioside (4MU-NAG ) as a substrate.
50
50 50
50
3
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Figure 2
(A) Structure-based sequence alignment of A. fumigatus ChiA1 and S. cerevisiae CTS1. AfChiA1
secondary structure elements are indicated above the sequence and labelled. Residue numbers are
given for AfChiA1. The ScCTS1 sequence is shaded by sequence similarity between the two enzymes
shown (black = identical, grey = chemically similar residues), while AfChiA1 is shaded by sequence
conservation among A. fumigatus ChiA enzymes (purple = 100% identity, then a gradient from blue
(mode identical) to white (less identical)). Residues lining the AfChiA1 active site are highlighted by
green filled circles. (B) Acetazolamide (slate) binding to the active site of AfChiA1. The protein is
shown as a grey cartoon with the side chains of active site residues shown as sticks and labelled.
Unbiased (i.e., calculated before the addition of the ligand to the model) σ -weighted F − F  density
for acetazolamide contoured at 3.0σ is shown in cyan. Possible hydrogen bonds are indicated as black
dotted lines, a water participating in indirect hydrogen bonding between ligand and protein is shown
as a red sphere. (C) The active site cavity of AfChiA1 (with bound acetazolamide) coloured by
similarity among AfChiA proteins as described for panel A. Y125, the only non-conserved residue of
the acetazolamide-binding site, is labelled.
A o c
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Scheme 1
Synthesis of acetazolomide analogues.
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Table 1
Inhibitors of ScCTS1 and their activity against AfChiA1
Name Allosamidin 8-Chloro-theophylline Acetazolamide Kinetin
Structure
ScCST1 K 0.61 340 21 3.2
AfChiA1 IC 127 410 164 >1000
hCHT IC 0.04 >2500 >1000 >1000
All data given in µM. hCHT is human chitinase. Data for ScCST1 have been reported previously.  The
IC  of allosamidin against hCHT has been reported previously.
i
50
50
19
50
22
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Table 2
X-ray diffraction/refinement statistics for the AfChiA1–acetazolamide complex
Resolution range (Å) 20.00–2.00 (2.05–2.00)
Number of observed reflections 27,0663
Number of unique reflections 67,879 (4270)
Completeness (%) 98.1 (92.9)
Redundancy 4.0 (3.5)
I/σ(I) 13.5 (2.5)
R 0.085 (0.522)
Wilson B (Å ) 22.5
R , R 0.216, 0.249
Bond length rmsd from ideality (Å) 0.017
Bond angle rmsd from ideality (°) 1.5
<B>, overall (Å ) 27.2
<B>, protein (Å ) 26.5
<B>, solvent (Å ) 34.1
<B>, ligand (Å ) 32.1
Ramachandran plot
 Most favoured (%) 88.6
 Additionally allowed (%) 10.8
 Generously allowed (%) 00.2
Values in parentheses pertain to the highest resolution shell. Ramachandran plot statistics were
calculated with PROCHECK.
merge
2
work free
2
2
2
2
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Table 3
Activity of compounds investigated
Compd IC  (µM) Hill slope L.E. % inhibition at 1 mM
R R
1 –SO NH –NHCOCH 164 ± 75 1.1 −0.40 88
2 –SO NH –NHCOCH CH 315 ± 65 0.71 −0.34 76
3 –SO NH –NHCO(CH ) CH >1000 33
4 –SO NH –NHCOCH(CH ) >1000 N/A N/A
5 –SO NH –NHCOPh 850 ± 74 0.5 −0.23 51
6 –SO NH –NH >1000 N/A N/A
7 –H –NHCOCH >1000 N/A 25
8 –Me –NHCOCH >1000 N/A N/A
9 –SH –NHCOCH 730 ± 120 1.1 −0.43 64
10 –Ph –NHCOCH 479 ± 210 0.5 −0.30 60
11 –CF –NHCOCH 141 ± 210 1.1 −0.44 91
12 –Br –NHCOCH 243 ± 98 0.7 −0.65 76
13 –NHCOCH >1000 N/A 22
14 –NHCOCH >1000 38
15 –Ph –NHCOCF 320 ± 60 1.2 −0.26 85
16 Morpholino –NHCOCF >1000 N/A 22
17 –NHCOCF >1000 N/A 30
18 –Et –NHCOCH CH >1000 N/A 18
19 –Me –NH >1000 N/A 21
20 –CH CH(CH ) –NHCOCH Cl >1000 N/A N/A
21 –CF –NHCOCH Cl >1000 N/A N/A
22 –CF –CO(CH ) CO H >1000 N/A N/A
Allosamidin 127 −0.12
8-Chloro-theophylline 410 −0.33
Kinetin >1000
L.E. = ligand efficiency in kcal mol  atom .  This was calculated from the equation:
∆G = −RT ln(1/IC ). IC  standard deviations calculated with 95% confidence limit.
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